Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 53-61

  Bouhnik, Anne Deborah ^a   Préau, Marie ^a,b   Vincent, Emmanuelle ^a   Carrieri, Maria Patrizia ^a   Gallais, Hervé ^c   Lepeu, Gérard ^d   Gastaut, Jean Albert ^e   Moatti, Jean Paul ^a   Spire, Bruno ^a  

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d Avignon Hospital   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; DEPRESSION; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; INTRAVENOUS DRUG ABUSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGICAL ASPECT; SUBSTANCE ABUSE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DEPRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 18344370128     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Junghans C, Low N, Chan P, Witschi A, Vernazza P & Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13:2547-2554.
2. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A & Lundgren JD. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. Journal of Acquired Immune Deficiency Syndromes 1999; 22:369-378.
3. Poundstone KE, Chaisson RE & Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral tnerapy. AIDS 2001; 15:1115-1123.
4. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV & Hogg RS. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16:2065-2072.
5. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR & Moss A. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183.
6. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP & Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14:151-155.
7. Lucas GM, Cheever LW, Chaisson RE & Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 2001; 27:251-259.
8. Gordillo V, del Amo J, Soriano V & Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-1769.
9. Schuman P, Ohmit SE, Moore J, Schoenbaum E, Boland R, Rompalo A & Solomon L. Human Immunodeficiency Virus Epidemiology Research Study. Perceived need for and use of mental health services by women living with or at risk of human immunodeficiency virus infection. Journal of American Medical Women's Association 2001; 56:4-8.
10. Moore RD, Keruly JC & Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. Journal of Acquired Immune Deficiency Syndromes 2004; 35:46-51.
11. Palepu A, Yip B, Miller C, Strathdee SA, O'Shaughnessy MV, Montaner JS & Hogg RS. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001; 15:423-424.
12. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS & Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes 2003; 32:522-526.
13. Leserman J, Petitto JM, Perkins DO, Folds JD, Golden RN & Evans DE. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Archives of General Psychiatry 1997; 54:279-285.
14. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ & Moore J. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. Journal of the American Medical Association 2001; 285:1466-1474.
15. Kilbourne AM, Justice AC, Rollman BL, McGinnis KA, Rabeneck L, Weissman S, Smola S, Schultz R, Whittle J & Rodriguez-Barradas M. Clinical importance of HIV and depressive symptoms among veterans with HIV infection. Journal of General International Medicine 2002; 17:512-520.
16. Bouhnik AD, Chesney M, Carrieri P, Gallais H, Moreau J, Moatti JP, Obadia Y & Spire B. Nonadherence among HIV-infected injecting drug users: the impact of social instability. Journal of Acquired Immune Deficiency Syndromes 2002; 31(Suppl 3):S149-153.
17. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C & Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. Journal of Epidemiology & Community Health 1999; 53:4-8.
18. Fuhrer F & Rouillon F. [The French version of the CES-D scale. Description and translation of the autoevaluation scale]. Psychiatrie & Psychobiologie 1989; 4:163-166. French.
19. Radloff E. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychology Measurement 1977; 3:385-401.
20. Eyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, VanRaden MJ, Treisman GJ & Morgenstern H. Depressive symptoms as predictors of medical outcomes in HIV infection. Multicenter AIDS Cohort Study. Journal of the American Medical Association 1993; 270:2563-2567.
21. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ME & Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. Journal of the American Medical Association 1993; 270:2568-2573.
22. Eyketsos CG, Hoover DR, Guccione M, Dew MA, Wesch J, Bing EG & Treisman GJ. Depressive symptoms over the course of HIV infection before AIDS. Social Psychiatry & Psychiatric Epidemiology 1996; 31:212-219.
23. Low-Beer S, Chan K, Yip B, Wood E, Montaner JS, O'Shaughnessy MV & Hogg RS. Depressive symptoms decline among persons on HIV protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 2000; 23:295-301.
24. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC & Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Archives of Internal Medicine 1996; 156:2233-2238.
25. Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G & Moatti JP. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. International Journal of Behavioral Medicine 2003; 10:1-14.
26. Spire B, Duran S, Souville M, Leport C, Raffi F & Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Science Medicine 2002; 54:1481-1496.
27. Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, Izzo C, Scalzini A, d'Arminio Monforte A, Wu AW & Antinori A. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2002; 31(Suppl 3):S136-139.
28. Latkin CA & Mandell W Depression as an antecedent of frequency of intravenous drug use in an urban, nontreatment sample. International Journal of Addiction 1993; 28:1601-1612.
29. Valente SM. Depression and HIV disease. Journal of Association of Nurses in AIDS Care 2003; 14:41-51.
30. Katz MH, Douglas JM Jr, Bolan GA, Marx R, Sweat M, Park MS & Buchbinder SP. Depression and use of mental health services among HIV-infected men. AIDS Care 1996; 8:433-442.
31. Ciesla JA & Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry 2001; 158:725-730.
32. Johnson JG, Rabkin JG, Lipsitz JD, Williams JB & Retnien RH. Recurrent major depressive disorder among human immunodeficiency virus (HIV)-positive and HIV-negative intravenous drug users: findings of a 3-year longitudinal study. Comprehensive Psychiatry 1999; 40:31-34.
33. Marimoutou C, Carrieri P, Poizot-Martin I, Loundou A, Tremolieres F, Rey D & Obadia Y. Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. AIDS Care 2003; 15:729-734.
34. Lyketsos CG, Hoover DR & Guccione M. Depression and survival among HIV-infected persons. Journal of the American Medical Association 1996; 275:35-36.
35. Evans DL, Leserman J, Perkins D, Gettes D, Zheng B, Zaytoun A, Rosier J, Folds J, Golden R & Pettito J. Stress and depression effect immunity and disease progression in HIV infection. Biological Psychiatry 1997; 42:207.
36. Leserman J. The effects of depression, stressful life events, social support, and coping on the progression of HIV infection. Current Psychiatry Report 2000; 2:495-502.
37. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, McCutchan JA, Straits-Troster K, Chandler JL & Grant I. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. HIV Neurobehavioral Research Center Group. Psychiatry 1995; 58:299-312.
38. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biological Psychiatry 2003; 54:295-306.
39. Cruess DG, Petitto JM, Leserman J, Douglas SD, Gettes DR, Ten Have TR & Evans DL. Depression and HIV infection: impact on immune function and disease progression. CNS Spectrums 2003; 8:52-58.
40. Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, Chene G, Leport C, Moatti JP & Spire B. Impact of early versus late adherence to highly active anti-retroviral therapy on immuno-virological response: a 3-year follow-up study. Antiviral Therapy 2003; 8:585-594.
41. Bouhnik AD, Carrieri MP, Rey D, Spire B, Gastaut JA, Gallais H & Obadia Y; MANIF 2000 Study Group. Drug injection cessation among HIV-infected injecting drug users. Addictive Behaviors 2004; 29:1189-1197.
42. Carrieri MP, Rey D, Loundou A, Lepeu G, Sobel A & Obadia Y. Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug & Alcohol Dependence 2003; 72:13-21.
43. Rabkin JG, Johnson J, Lin SH, Lipsitz JD, Remien RH, Williams JB & Gorman JM. Psychopathology in male and female HIV-positive and negative injecting drug users: longitudinal course over 3 years. AIDS 1997; 11:507-515.
44. Semple SJ, Patterson TL, Straits-Troster K, Atkinson JH, McCutchan JA & Grant I. Social and psychological characteristics of HIV-infected women and gay men. HIV Neurobehavioral Research Center (HNRC) Group. Women & Health 1996; 24:17-41.
45. Miller LG & Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. AIDS Reader 2000; 10:177-185.
46. Wagner GJ & Rabkin JG. Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care 2000; 12:405-408.
47. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger ID, Chesney MA &: Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
48. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA & Schoenbaum EE. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases 2001; 33:1417-1423.
49. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JG, Costagliola D, Lacarelle B & Moatti JP. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviraltherapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001; 15:1075-1077.
50. Latkin CA, Vlahov D & Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88:517-526.
51. Darke S. Self-report among injecting drug users: a review. Drug & Alcohol Dependence 1998; 51:253-263; discussion 267-268.
52. Greenfield L, Bigelow GE & Brooner RK. Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors. Drug & Alcohol Dependence 1995; 39:91-98.
53. Messiah A, Loundou AD, Maslin V, Lacarelle B & Moatti JP. Physician recognition of active drug use in HIV-infected patients is lower than validity of patient's self-reported drug use. Journal of Pain & Symptom Management 2001; 21:103-112.
54. Mulrow CD, Williams JW Jr, Gerety MB, Ramirez G, Montiel OM & Kerber C. Case-finding instruments for depression in primary care settings. Annals of Internal Medicine 1995; 122:913-921.
55. Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, Campbell JV, Garfein RS, Thomas DL & Strathdee SA. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. Journal of Urban Health 2004; 81:278-290.
56. Kalichman SC, Rompa D & Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. Journal of Nervous & Mental Disease 2000; 188:662-670.
57. Palella FJ Jr, Chmiel JS, Moorman AC & Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-1626.
58. Pradier C, Bentz L, Spire B, Tourette-Turgis C, Morin M, Souville M, Rebilion M, Fuzibet JG, Pesce A, Dellamonica P & Moatti JP. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clinical Trials 2003; 4:121-131.
59. Goujard C, Bernard N, Sohier N, Peyramond D, Lancon F, Chwalow J, Arnould B & Delfraissy JF. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes 2003; 34:191-194.